What does the evidence say about Glycine Cognition Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for Glycine Cognition Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - Background Social cognitive impairments are a fundamental aspect of schizophrenia, exerting a substantial influence on patients' functional outcomes. [Yamada Y (2026); evidence level 1] - However, to date, there have been no meta-analyses of comprehensive pharmacological interventions covering all domains of social cognition. [Yamada Y (2026); evidence level 1] - [ ] 7 8 Preclinical and clinical evidence indicate that cisplatin can cross the blood–brain barrier and accumulates in brain regions critical for learning and memory, particularly the hippocampus and prefrontal cortex. [Kazmi Hafiz Muhammad Obaid (2026); evidence level 4] - These molecular and cellular changes translate into impaired synaptic plasticity, reduced neurogenesis, and deficits in spatial learning and memory on standard behavioral tests,. [Kazmi Hafiz Muhammad Obaid (2026); evidence level 4] - We hypothesize that glycine administration will ameliorate cisplatin-associated deficits in spatial learning and working memory and that behavioral protection will align with reduced inflammatory signaling and preserved neuronal integrity. [Kazmi Hafiz Muhammad Obaid (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.